** Shares of gene therapy developer Sarepta Therapeutics SRPT.O up 2.1% to $63.21
** H.C. Wainwright raises SRPT's rating to "neutral" from "sell"
** Still expect Elevidys revenue to fall short in 2H25 — more so now after the recently reported patient death — expect a continued bolus demand effect from the June 2024 approval in older and non-ambulatory groups, brokerage says
** SRPT last month said a 16-year-old boy died from acute liver failure months after receiving U.S.-approved gene therapy Elevidys, for a rare muscular dystrophy
** Wainwright also believes there is a chance that the 2025 Elevidys ramp may sour faster—perhaps as soon as 2Q25— given the likelihood of increased hesitance by prescribers/patients
** The departure of U.S. FDA's top vaccine official, Peter Marks, casts uncertainty on the future of SRPT's development-stage portfolio - brokerage
** Up to last close, stock had fallen 49% YTD
(Reporting by Juby Babu in Mexico City)
((Juby.Babu@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。